Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Verrica Pharmaceuticals Inc. VRCA

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$35.6M
▲ 370.2% YoY
$-17.9M
$-17.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our commercial product, YCANTH (VP-102), was approved by the U.S. Food and Drug Administration, or FDA, in July 2023 for the treatment of molluscum in adult and pediatric patients two years of age and older. Our second development candidate, VP-315 (ruxotemitide), is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, or BCC. We have built a specialized sales organization consisting of approximately 40 field employee sales representatives as of December 31, 2025, in the United States focused on pediatric dermatologists, dermatologists, pediatricians and select other primary care health care providers, or HCPs. As of December 31, 2025, we had 76 full-time employees. We were incorporated under the laws of the State of Delaware on July 3, 2013.

Written from the business description in Verrica Pharmaceuticals Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 11 March 2026. Every sentence was checked against that document before publication.

Growth

USD 35.6M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 35.6 · Net income -17.9
15M30M-30M-60M
2017202020232025
Compound annual growth
+57.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−50 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -34.2% · Net -50.3%
-500%-1000%
201720212025
ROE
FY2023 · ROE -224.1%
-100%-200%
201720212025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -44%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -17.6
-25.0M-50.0M
201720212025

Total assetsUSD 47.1M
EquityUSD 24.7M
CashUSD 30.1M
Gross debtUSD 0.00
Net debtUSD -30.1M
Current ratio2.59×

The company holds more cash than debt.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VRCA, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.00.00.00.00.0◌◌◌◌
Operating income $B−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0◌
Income tax $B0.00.00.00.0◌◌◌◌◌
Net income $B−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0◌
EPS, diluted $−1.68−14.78−1.48−0.72−1.30−1.71−1.13−1.41−1.56
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %——−224.1−67.4−107.0−87.1−36.5——
Shares out B0.020.090.040.040.030.030.030.030.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 36 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 16 checks were skipped: cost of revenue is not tagged before 2023. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image